/CYXO.ST
CYXO.ST Stock - Cyxone AB (publ)
Healthcare|BiotechnologySTO
$0.02+0.00%
+$0.00 (+0.00%) • Dec 5
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.02
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CYXO.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.02 – $0.02
TARGET (TP)$0.02
STOP LOSS$0.02
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.42
52W High$0.16
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $5.15M | $6.40M | N/A | N/A | $26,569 |
| Gross Profit | $2.61M | $4.16M | $-1,794,000 | $-1,796,000 | $-35,029,609 |
| Gross Margin | 50.7% | 65.0% | N/A | N/A | -131843.9% |
| Operating Income | $-21,661,000 | $-42,435,000 | $-45,045,000 | $-49,000,000 | $-35,165,248 |
| Net Income | $-22,989,000 | $-42,467,000 | $-45,031,000 | $-49,000,000 | $-35,165,749 |
| Net Margin | -446.6% | -663.7% | N/A | N/A | -132356.3% |
| EPS | $-0.22 | $-0.44 | $-0.73 | $-0.79 | $-0.79 |
Company Overview
Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CYXO.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.02
Q3 2024
EPS Surprise History
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 27, 2025 | — | — | — | — |
Q2 2025 | May 12, 2025 | — | — | — | — |
Q1 2025 | Feb 25, 2025 | — | — | — | — |
Q4 2024 | Nov 29, 2024 | — | — | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.02 | — | — |
Q2 2024 | May 14, 2024 | — | $-0.02 | — | — |
Q1 2024 | Feb 27, 2024 | — | $-0.05 | — | — |
Q4 2023 | Oct 27, 2023 | — | $-0.05 | — | — |
Q3 2023 | Aug 30, 2023 | — | $-0.06 | — | — |
Q2 2023 | May 12, 2023 | — | $-0.06 | — | — |
Q1 2023 | Feb 17, 2023 | — | $-0.02 | — | — |
Q4 2022 | Oct 27, 2022 | — | $-0.11 | — | — |
Q3 2022 | Aug 24, 2022 | — | $-0.13 | — | — |
Q2 2022 | May 12, 2022 | — | $-0.18 | — | — |
Q1 2022 | Feb 22, 2022 | — | $-0.15 | — | — |
Q4 2021 | Oct 29, 2021 | — | $-0.17 | — | — |
Q3 2021 | Aug 27, 2021 | — | $-0.19 | — | — |
Q2 2021 | May 12, 2021 | — | $-0.14 | — | — |
Q1 2021 | Feb 12, 2021 | — | $-0.24 | — | — |
Q4 2020 | Nov 13, 2020 | — | $-0.25 | — | — |
Latest News
Loading news...
Frequently Asked Questions about CYXO.ST
What is CYXO.ST's current stock price?
Cyxone AB (publ) (CYXO.ST) is currently trading at $0.02 per share. The stock has moved +0.00% today.
What is the analyst price target for CYXO.ST?
No analyst price targets are currently available for this stock.
What sector is Cyxone AB (publ) in?
Cyxone AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is CYXO.ST's market cap?
Cyxone AB (publ) has a market capitalization of $0.01 billion, making it a small-cap company.
Does CYXO.ST pay dividends?
No, Cyxone AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASAP.ST
Asarina Pharma AB (publ)
$0.03
Mkt Cap: $0.0B
BONZUN.ST
Bonzun AB (publ)
$0.01
Mkt Cap: $0.0B
CLINE-B.ST
Cline Scientific AB (publ)
$0.07
Mkt Cap: $0.0B
DEAR.ST
Duearity AB (publ)
$0.02
Mkt Cap: $0.0B
HEMC.ST
Hemcheck Sweden AB (publ)
$0.23
Mkt Cap: $0.0B
IDOGEN.ST
Idogen AB (publ)
$0.12
Mkt Cap: $0.0B
PHARM.ST
Pharmiva AB (publ)
$0.56
Mkt Cap: $0.0B
REDW.ST
Redwood Pharma AB
$1.19
Mkt Cap: $0.0B
SCOL.ST
Scandion Oncology A/S
$0.00
Mkt Cap: $0.0B
ZICC.ST
Ziccum AB (publ)
$0.25
Mkt Cap: $0.0B
Explore stocks similar to CYXO.ST for comparison